New drug options for advanced prostate cancer

13 December 2012

Prostate cancer is becoming increasingly common due to globally growing numbers of elderly men, and scientists are fighting to create new treatment options for patients with advanced disease, states a new report by health care experts GlobalData.

This states that the prostate cancer market has historically been dominated by chemotherapies and hormone therapies, with major players including AstraZeneca (LSE: ANZ), which market the hormone therapies Zoladex (goserelin acetate) and Casodex (bicalutamide), and Sanofi (Euronext: SAN), which market the popular chemotherapies Taxotere (docetaxel) and Jevtana (cabazitaxel).

Hormone therapies will continue to be a mainstay of prostate cancer treatment, but the role of chemotherapies will be reduced as targeted therapies like Johnson & Johnson’s (NYSE: JNJ) Zytiga (abiraterone acetate) and Medivation (Nasdaq: MDVN)/Astellas’(TYO: 4503) Xtandi (enzalutamide) become the most popular treatment options for metastatic castration-resistant prostate cancer (mCRPC).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK